Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06255678
Other study ID # AFFE-PCI
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 3, 2023
Est. completion date January 1, 2027

Study information

Verified date February 2024
Source Medical University of Warsaw
Contact Mariusz Tomaniak, MD PhD
Phone +48 22 5991951
Email mariusz.tomaniak@wum.edu.pl
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Fractional flow reserve (FFR) has revolutionized the diagnosis and treatment of coronary artery disease (CAD), and more recently, post percutaneous coronary intervention (post-PCI) FFR has emerged as an independent predictor of cardiovascular events, enabling the identification of cases requiring additional optimization of the implanted stent. Modern technologies allow less invasive alternatives to traditional FFR measurement - angiography-based vessel fractional flow reserve (vFFR) and derivative ΔvFFR, which is calculated by a difference between the post-PCI vFFR and pre-PCI vFFR. In large clinical studies, the good accuracy between vFFR and FFR - measured before and after PCI - has been confirmed. However, insufficient data is available about the value of post-vFFR and ΔvFFR as prognostic values and indicators of patient health. This is a prospective multicenter register study analyzing the association between the value of ΔvFFR, vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L). Patients undergoing PCI for chronic coronary syndromes (CCS), non-ST-segment elevation acute coronary syndromes (NST-ACS) or ST-Segment Elevation Myocardial Infarction (STEMI) will be enrolled in this study.


Description:

The primary goal of this prospective multicenter register study is to evaluate the association between the value of vFFR after PCI and adverse clinical outcomes, residual angina and quality of life using the validated Seattle Angina Questionnaire (SAQ) and EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L) at 6 and 24 months following PCI. The primary composite endpoint is defined as a major adverse cardiovascular event (MACE) including all-cause death, target-vessel myocardial infarction (TVMI), and target vessel revascularization (TVR)] at 6, 12 and 24-month follow-ups. Patients undergoing PCI for chronic coronary syndromes (CCS), non-ST-segment elevation acute coronary syndromes (NST-ACS) or or ST-Segment Elevation Myocardial Infarction (STEMI) will be enrolled in this study. The analyses of the primary endpoint will be stratified according to the following subgroups: - Diabetes/non-diabetes - Glomerular filtration rate (GFR)≥60/GFR<60 [ml/min./1,73m2] - Focal/diffuse atherosclerosis - Multivessel/single-vessel disease - CCS/NST-ACS/STEMI - CCS/ACS The patients' coronary angiograms will be analyzed using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands) enrolled at the Invasive Cardiology Unit of the 1st Department of Cardiology, Medical University of Warsaw (Poland) and other centers in Poland.


Recruitment information / eligibility

Status Recruiting
Enrollment 2005
Est. completion date January 1, 2027
Est. primary completion date January 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Percutaneous coronary intervention (PCI) for chronic coronary syndromes (CCS) or acute coronary syndromes (ACS) - Adequate quality of angiogram enabling vFFR analysis (available two angiographic views with =30° differences in rotation/angulation, the possibility of vessel contour selection, proper quality of the images, vessels without severe overlapping, tortuosity, foreshortening and poor vessel opacification) - Age >18 years - The patient's written informed consent has been obtained before the procedure Exclusion Criteria: - Cardiogenic shock, pulmonary oedema - Severe hemodynamical instability - Prior coronary artery bypass grafting (CABG) - Active bleeding - Acute and chronic inflammatory conditions - Acute mechanical complications of myocardial infarction - Congenital heart disease - Heart transplantation - Non-cardiac comorbidities with a life expectancy of less than 1 year

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Angiography-based vessel fractional flow reserve (vFFR) calculation
vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)

Locations

Country Name City State
Poland Medical University of Warsaw Warsaw

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Warsaw

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of MACE defined as all-cause death, target-vessel myocardial infarction (TVMI) and target vessel revascularization (TVR). 24 months
Secondary Rate of MACE defined as all-cause death, target-vessel myocardial infarction (TVMI) and target vessel revascularization (TVR). 6 months, 12 months
Secondary Rate of all-cause death 6 months, 12 months, 24 months
Secondary Rate of target-vessel myocardial infarction (TVMI) 6 months, 12 months, 24 months
Secondary Rate of target-vessel target vessel revascularization (TVR) 6 months, 12 months, 24 months
Secondary Symptoms of angina and quality of life assessed by the score of EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L) The EQ-5D-5L scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function. 6 months, 12 months, 24 months
Secondary Symptoms of angina and quality of life assessed by score of the Seattle Angina Questionnaire (SAQ) The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score. 6 months, 12 months, 24 months
Secondary Correlation of post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) with score of Seattle Angina Questionnaire (SAQ). The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score. vFFR values are within the range 0-1, where higher values indicate better function. 6 months, 12 months, 24 months
Secondary Correlation of ?vFFR with score of Seattle Angina Questionnaire (SAQ). The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score. 6 months, 12 months, 24 months
Secondary Correlation of post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) with score of EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L). The EQ-5D-5L scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function. vFFR values are within the range 0-1, where higher values indicate better function. 6 months, 12 months, 24 months
Secondary Correlation of ?vFFR with score of EuroQol 5-level 5-dimensional questionnaire (EQ-5D-5L). The EQ-5D-5L scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function. 6 months, 12 months, 24 months
Secondary AUC for the optimal cutoff point for post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) for significant prediction of MACE MACE defined as all-cause death, target-vessel myocardial infarction (TVMI) and target vessel revascularization (TVR). 6 months, 12 months, 24 months
Secondary AUC for the optimal cutoff point for ?vFFR useful for prediction of MACE MACE defined as all-cause death, target-vessel myocardial infarction (TVMI) and target vessel revascularization (TVR). 6 months, 12 months, 24 months
Secondary AUC for the optimal cutoff point for post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) useful for prediction of higher than median SAQ score. The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score. vFFR values are within the range 0-1, where higher values indicate better function. 6 months, 12 months, 24 months
Secondary AUC for the optimal cutoff point for post-percutaneous coronary intervention (PCI) vessel fractional flow reserve (vFFR) useful for prediction of higher than median EQ-5D-5L score. The scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function. vFFR values are within the range 0-1, where higher values indicate better function. 6 months, 12 months, 24 months
Secondary AUC for the optimal cutoff point for ?vFFR useful for prediction of higher than median SAQ score. The SAQ provides results for 6 categories. The patient can receive between 0 and 100 points in each category, where 100 represents the best score. 6 months, 12 months, 24 months
Secondary AUC for the optimal cutoff point for ?vFFR useful for prediction of higher than median EQ-5D-5L score. The scale asses the patient's self-rated health in five categories (each category 1-5) - higher values indicate worse performance. Additionally, the patient fulfill vertical visual analog scale from 0 to 100, where higher scores indicate better function. 6 months, 12 months, 24 months
Secondary Rate of revascularization of any vessel due to exacerbation of angina symptoms. Decisions on the performance of revascularization will be made by the attending physician according to the clinical features and available methods. 6 months, 12 months, 24 months
Secondary Rate of definite and probable stent thrombosis. 6 months, 12 months, 24 months
Secondary Rate of clinically driven invasive coronary angiography due to exacerbation of angina symptoms. Decisions on the performance of invasive coronary angiography will be made by the attending physician according to the clinical features. 6 months, 12 months, 24 months
Secondary AUC for the value of in-stent vFFR gradient in predicting the rate of MACE vFFR values are within the range 0-1, where higher values indicate better function. 6 months, 12 months, 24 months
Secondary AUC for the value of 3-vessel post-PCI vFFR burden (sum of the vFFR estimated in the three main epicardial arteries) in predicting the rate of MACE 3-vessel post-PCI vFFR will be defined as the sum of the post-PCI vFFR values derived for each vessel (left anterior descending, circumflex, right coronary artery). 6 months, 12 months, 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study